Revenue Breakdown
Composition ()
No data
Revenue Streams
Arcus Biosciences Inc (RCUS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is License and development services revenue, accounting for 76.9% of total sales, equivalent to $20.00M. Another important revenue stream is Collaboration revenue. Understanding this composition is critical for investors evaluating how RCUS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Arcus Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -345.45%, while the net margin is -321.21%. These profitability ratios, combined with a Return on Equity (ROE) of -63.26%, provide a clear picture of how effectively RCUS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RCUS competes directly with industry leaders such as IRON and DYN. With a market capitalization of $3.00B, it holds a leading position in the sector. When comparing efficiency, RCUS's gross margin of 100.00% stands against IRON's N/A and DYN's N/A. Such benchmarking helps identify whether Arcus Biosciences Inc is trading at a premium or discount relative to its financial performance.
